Balyasny Asset Management
BLUE

Balyasny Asset Management’s bluebird bio BLUE Stock Holding History

Balyasny Asset Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8,376
Closed -$18.5M – 1786
2018
Q1 		$18.5M Buy
+8,376
New +$21.3M 0.08% 346
2017
Q4 		– Sell
-11,580
Closed -$20.6M – 2061
2017
Q3 		$20.6M Buy
+11,580
New +$16.2M 0.08% 320

Other funds holding BLUE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balyasny Asset Management's BLUE Position: Q3 2024 in Review

Balyasny Asset Management sold out of bluebird bio (BLUE) in Q3 2024, closing a stake of 11,350 shares — an estimated $223K sold.

Balyasny Asset Management first reported a position in BLUE in Q3 2015 and held it in 24 quarters. The position peaked at $69.1M in Q3 2017. 140 funds tracked by Wall St. Rank hold BLUE as of Q3 2024.

  • Balyasny Asset Management reported no remaining bluebird bio position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 11,350 bluebird bio shares in Q3 2024, an estimated $223K.
  • Balyasny Asset Management first reported a position in bluebird bio in Q3 2015 and held it in 24 quarters.
  • Balyasny Asset Management's bluebird bio position peaked at $69.1M in Q3 2017.
  • 140 funds tracked by Wall St. Rank held bluebird bio as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.